The trial investigated the expression of HIF-1α and HIF-1α regulated genes CA-9, VEGF, and GLUT by immunohistochemistry and mRNA-sequencing in the tumor tissue of breast cancer patients who received daily digoxin for 14 days or no therapy preoperatively. This evidence concerns the gene HIF1A and neoplasm.